Top

World Journal of Surgery

Published in:

01-11-2012

Prognostic MicroRNAs in Cancer Tissue from Patients Operated for Pancreatic Cancer—Five MicroRNAs in a Prognostic Index

Authors: Nicolai A. Schultz, Klaus K. Andersen, Anne Roslind, Hanni Willenbrock, Morten Wøjdemann, Julia S. Johansen

Published in: World Journal of Surgery | Issue 11/2012

Abstract

Background

The aim of the present study was to identify a panel of microRNAs (miRNAs) that can predict overall survival (OS) in non micro-dissected cancer tissues from patients operated for pancreatic cancer (PC).

Methods

MiRNAs were purified from formalin-fixed paraffin embedded (FFPE) cancer tissue from 225 patients operated for PC. Only a few of those patients received adjuvant chemotherapy. Expressions of miRNAs were determined with the TaqMan MicroRNA Array v2.0. Two statistical methods, univariate selection and the Lasso (Least Absolute Shrinkage and Selection Operator) method, were applied in conjunction with the Cox proportional hazard model to relate miRNAs to OS.

Results

High expression of miR-212 and miR-675 and low expression of miR-148a*, miR-187, and let-7g* predicted short OS independent of age, gender, calendar year of operation, KRAS mutation status, tumor stage, American Society of Anesthesiologists (ASA) score, localization (not miR-148a*), and differentiation of tumor. A prognostic index (PI) based on these five miRNAs was calculated for each patient. The median survival was 1.09 years (Confidence Interval [CI] 0.98–1.43) for PI > median PI compared to 2.23 years (CI 1.84–4.36) for PI < median. MiR-212, miR-675, miR-187, miR-205, miR-944, miR-431, miR-194*, miR-148a*, and miR-769-5p showed the strongest prediction ability by the Lasso method. Thus miR-212, miR-675, miR-187, and miR-148a* were predictors for OS in both statistical methods.

Conclusions

The combination of five miRNAs expression in non micro-dissected FFPE PC tissue can identify patients with short OS after radical surgery. The results are independent of chemotherapy treatment. Patients with a prognostic index > median had a very short median OS of only 1 year.

Available only for authorised users

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29PubMedCrossRef

Hildago M (2010) Pancreatic cancer. N Engl J Med 362:1605–1612CrossRef

Wagner M, Redaelli C, Lietz M et al (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586–594PubMedCrossRef

Beger HG, Thorab FC, Liu Z et al (2004) Pathogenesis and treatment of neoplastic diseases of the papilla of Vater: Kausch-Whipple procedure with lymph node dissection in cancer of the papilla of Vater. J Hepatobiliary Pancreat Surg 11:232–238PubMedCrossRef

Bettschart V, Rahman MQ, Engelken FJ et al (2004) Presentation, treatment and outcome in patients with ampullary tumours. Br J Surg 91:1600–1607PubMedCrossRef

Locker GY, Hamilton S, Harris J et al (2006) 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327PubMedCrossRef

Nelson KM, Weiss GJ (2008) MicroRNAs and cancer: past, present and potential future. Mol Cancer Ther 7:3655–3660PubMedCrossRef

Bartels CL, Tsongalis GJ (2009) MicroRNAs: novel biomarkers for human cancer. Clin Chem 55:623–631PubMedCrossRef

Iorio MV, Croce CM (2009) MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27:5848–5856PubMedCrossRef

10.

Visone R, Croce CM (2009) MiRNAs and cancer. Am J Pathol 174:1131–1138PubMedCrossRef

11.

Farazi TA, Spitzer JI, Morozov P et al (2011) MiRNAs in human cancer. J Pathol 223:102–115PubMedCrossRef

12.

Li J, Smyth P, Flavin R et al (2007) Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 7:36PubMedCrossRef

13.

Zhang X, Chen J, Radcliffe T et al (2008) An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 10:513–519PubMedCrossRef

14.

Rachagani S, Kumar S, Batra SK (2010) MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett 292:8–16PubMedCrossRef

15.

Bloomston M, Frankel WL, Petrocca F et al (2007) MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297:1901–1908PubMedCrossRef

16.

Szafranska AE, Davison TS, John J et al (2007) MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26:4442–4452PubMedCrossRef

17.

Dillhoff M, Liu J, Frankel W et al (2008) MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12:2171–2176PubMedCrossRef

18.

Szafranska AE, Doleshal M, Edmunds HS et al (2008) Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 54:1716–1724PubMedCrossRef

19.

Habbe N, Koorstra JB, Mendell JT et al (2009) miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 8:340–346PubMedCrossRef

20.

Seux M, Iovanna J, Dagorn J-C et al (2009) MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues. Pancreatology 9:66–72PubMedCrossRef

21.

Wang J, Chen J, Chang P et al (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res 2:807–813CrossRef

22.

Zhang Y, Li M, Wang H et al (2009) Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 33:698–709. doi:10.1007/s00268-008-9833-0 PubMedCrossRef

23.

Greither T, Grochola LF, Udelnow A et al (2010) Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 126:73–80PubMedCrossRef

24.

Hwang JH, Voortman J, Giovannetti E et al (2010) Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 5:e10630PubMedCrossRef

25.

Ikenaga N, Ohuchida K, Mizumoto K et al (2010) MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol 17:3120–3128PubMedCrossRef

26.

Ali S, Almhanna K, Chen W et al (2011) Differential expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 3:28–47

27.

Kong X, Du Y, Wang G et al (2011) Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci 56:602–609PubMedCrossRef

28.

Ohuchida K, Mizumoto K, Kayashima T et al (2011) MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol 18:2381–2387PubMedCrossRef

29.

Schultz NA, Werner J, Willenbrock H et al (2012) MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Modern Pathol (in press)

30.

Preis M, Gardner TB, Gordon SR et al (2011) MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 17:5812–5821PubMedCrossRef

31.

Jamieson NB, Morran DC, Morton JP et al (2012) MicroRNA profiles associated with diagnosis, clinicopathological criteria and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18:534–545PubMedCrossRef

32.

McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef

33.

WHO Classification of Tumours (2000) Pathology and Genetics of Tumours of the Digestive System. IARC Press, Lyon

34.

Mar JC, Kimura Y, Schroder K et al (2009) Data-driven normalization strategies for high-throughput quantitative RT-PCR. BMC Bioinformatics 10:110PubMedCrossRef

35.

Bovelstad HM, Nygard S, Storvold HL et al (2007) Predicting survival from microarray data—a comparative study. Bioinformatics 23:2080–2087PubMedCrossRef

36.

Tibshirani R (1997) The LASSO method for variable selection in the Cox model. Stat Med 16:385–395PubMedCrossRef

37.

Grambsch P, Therneau T (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515–526CrossRef

38.

R Development Core Team (2007) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0

39.

Hanoun N, Delpu Y, Suriawinata AA et al (2010) The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem 56:1107–1118PubMedCrossRef

40.

Grutzmann R, Foerder M, Alldinger I et al (2003) Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 443:508–517PubMedCrossRef

41.

Buchholz M, Braun M, Heidenblut A et al (2005) Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24:6626–6636PubMedCrossRef

42.

Schultz NA, Roslind A, Christensen IJ et al (2011) Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas 41:759–766

43.

Torrisani J, Bournet B, du Rieu MC et al (2009) Let-7 microRNA transfer in pancreatic cancer derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gen Ther 20:831–844CrossRef

44.

Johnson SM, Grosshans H, Shingara J et al (2005) RAS is regulated by the let-7 microRNA family. Cell 120:635–647PubMedCrossRef

45.

Ragusa M, Majorana A, Statello L et al (2010) Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 9:3396–3409PubMedCrossRef

46.

Ferrone CR, Finkelstein DM, Thayer SP et al (2006) Perioperative CA 19–9 levels can predict stage and survival in patients with respectable pancreatic adenocarcinoma. J Clin Oncol 24:2897–2902PubMedCrossRef

47.

Smith RA, Bosonnet L, Ghaneh P et al (2008) Preoperative CA 19–9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 25:226–232PubMedCrossRef

48.

Nikiforova MN, Tseng GC, Steward D et al (2008) MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93:1600–1608PubMedCrossRef

49.

Hatakeyama H, Cheng H, Wirth P et al (2010) Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 5:e12702PubMedCrossRef

50.

Tsang WP, Ng EK, Ng SS et al (2010) Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31:350–358PubMedCrossRef

Title: Prognostic MicroRNAs in Cancer Tissue from Patients Operated for Pancreatic Cancer—Five MicroRNAs in a Prognostic Index
Authors: Nicolai A. Schultz
Klaus K. Andersen
Anne Roslind
Hanni Willenbrock
Morten Wøjdemann
Julia S. Johansen
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 11/2012
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-012-1705-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic MicroRNAs in Cancer Tissue from Patients Operated for Pancreatic Cancer—Five MicroRNAs in a Prognostic Index

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2012

Early Detection of Hypocalcemia After Total/Completion Thyroidectomy: Routinely Usable Algorithm Based on Serum Calcium Level

Comparison of Laparoscopic Cholecystectomy for Acute Cholecystitis within and Beyond 72 h of Symptom Onset During Emergency Admissions

Randomized Controlled Trial of Tamsulosin for Prevention of Acute Voiding Difficulty After Rectal Cancer Surgery

Survey of Surgery and Anesthesia Infrastructure in Ethiopia

Survival Benefit of Palliative Gastrectomy in Gastric Cancer Patients with Peritoneal Metastasis

Routine Chest X-Ray Prior to Thyroid Surgery: Is It Always Necessary?